Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 31 to 40 of 41

TitleReference numberPublishedLast updated
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA496
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxaneTA458
Everolimus with exemestane for treating advanced breast cancer after endocrine therapyTA421
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimensTA423
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancerTA424
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancerTA263
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2TA257
Fulvestrant for the treatment of locally advanced or metastatic breast cancerTA239
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancerTA214
Gemcitabine for the treatment of metastatic breast cancerTA116

Results per page

  1. 10
  2. 25
  3. 50
  4. All